RxDoctor Payments Data

Anders Carlson, MD

Endocrinology, Diabetes & Metabolism · St Louis Park, MNNPI 1720254725

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Medtronic at 39.8% of the total. Among endocrinology, diabetes & metabolism clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$162,896in general payments, 2019–2025

Across 177 payments — averaging $920.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$65K
  • Abbott$40K
  • Novo Nordisk$19K
  • Insulet Corporation$15K
  • Mannkind Corporation$10K
  • Eli Lilly$4K
  • plus $9K from 9 others
$5,427,332in research payments, 2019–2025

Across 491 payments — averaging $11,054 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$3.1M
  • Insulet Corporation$1.5M
  • Eli Lilly$267K
  • Sequel Med Tech, LLC$196K
  • Novo Nordisk AS$168K
  • Tandem Diabetes Care, Inc.$104K
  • plus $87K from 3 others

What the payments were for

  • Consulting fees$53,76133%
  • Speaking & faculty fees$87,07853%
  • Travel & lodging$17,67811%
  • Food & beverage$4,3363%
  • Gifts$430%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)76$64,888
Abbott8$40,124
Novo Nordisk12$19,298
Insulet Corporation19$14,862
Mannkind Corporation18$10,089
Eli Lilly23$4,460
Zealand Pharma A/s2$3,560
Lilly USA, LLC1$1,575
Ascensia Diabetes Care US Inc.1$1,500
Novo Nordisk AS7$866
Sanofi-aventis U.S. LLC3$720
Companion Medical, Inc.1$500
Dexcom, Inc.3$280
Polarityte, Inc.2$122
Senseonics, Incorporated1$53

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$162,896 in reported general payments places this provider in the 95th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.

See all endocrinology, diabetes & metabolism providers in Minnesota

Medicare billing

Part B allowed, 2024
$37,283
Medicare patients
348
Services billed
692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in St Louis Park

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →